By Precious Dipe
Eritrea has become the 11th country in the World Health Organization (WHO) African Region to eliminate trachoma as a public health problem, marking a major breakthrough in the fight against one of the world's leading infectious causes of blindness.
The WHO validation makes Eritrea the 34th country globally to achieve the milestone, following two decades of sustained interventions targeting the disease, particularly in remote rural communities where poor access to clean water, sanitation and healthcare had fuelled its spread.
Eritrea is also the 66th country globally and the 23rd in the WHO African Region to eliminate at least one neglected tropical disease.
Congratulating the country, WHO Director-General, Dr Tedros Adhanom Ghebreyesus, described the achievement as a victory for communities that had endured the devastating effects of the disease.
“I congratulate the Government and people of Eritrea on this historic achievement,” Tedros said.
“After two decades of determined effort, Eritrea has consigned trachoma as a public health problem to history. This is a victory for the communities most affected by this devastating disease, and a powerful example of what sustained national commitment can achieve.”
Eritrea's success followed nationwide surveys conducted between 2006 and 2020, which helped identify affected communities and guide the rollout of interventions across the country.
The government subsequently implemented WHO's recommended SAFE strategy, a combination of surgery for advanced cases, antibiotics to clear infection, facial cleanliness to limit transmission and environmental improvements, particularly better access to water and sanitation.
The programme covered all 58 sub-zobas, the country's second-level administrative areas, with interventions scaled up in communities where the disease remained endemic.
A notable feature of the campaign was its community-led sanitation approach, which delivered significant public health gains despite limited external funding.
Health workers also deployed digital tools for data collection and mapping to identify affected populations, track disease patterns and direct resources to hard-to-reach communities.
The antibiotic component relied largely on oral azithromycin donated by Pfizer Inc. through the International Trachoma Initiative.
WHO Regional Director for Africa, Dr Mohamed Janabi, said Eritrea's achievement demonstrated the impact of political commitment, community participation and effective partnerships in tackling neglected tropical diseases.
“I congratulate Eritrea on this historic public health milestone. It shows what is possible through sustained political commitment, community leadership and strong partnerships,” Janabi said.
He added that the achievement offered encouragement to other African countries still battling trachoma.
“Eritrea’s achievement brings us closer to a world free from the suffering caused by neglected tropical diseases and sends a strong message of hope to other African countries working towards trachoma elimination. With determination and collective action, we can protect the health and well-being of communities and leave no one behind.”
WHO Representative to Eritrea, Dr Mary Stephen, attributed the success to national ownership and collaboration among communities, the Ministry of Health, the Fred Hollows Foundation, development partners and frontline health workers.
"This success belongs first and foremost to the people of Eritrea. The elimination of trachoma as a public health problem is the result of strong national leadership and ownership, and collaboration between communities, the Ministry of Health, the Fred Hollows Foundation, development partners and health workers across the country,” she said.
Stephen said WHO would continue working with the government and its partners to sustain the gains and prevent a resurgence of the disease.
Although Eritrea has crossed the elimination threshold, the country has established systems to identify and manage new cases of trachomatous trichiasis, the advanced stage of the disease, and will continue surveillance to detect any recurrence.
Nigeria intensifies elimination push
While Eritrea has secured WHO validation, Nigeria is making significant progress towards eliminating trachoma, although the disease remains a public health challenge in some parts of the country.
The Federal Ministry of Health and Social Welfare disclosed in July 2026 that 11 local government areas (LGAs) remained to achieve elimination status out of 134 previously identified endemic LGAs.
The country has stopped mass drug administration (MDA) in 116 LGAs after they met the WHO elimination threshold, representing approximately 87 per cent progress towards eliminating the disease in affected areas.
Director and Programme Manager of the National Trachoma Programme, Nicholas Olobio, said Nigeria had also performed more than 100,000 surgeries for trachomatous trichiasis, the advanced stage of the disease that can cause irreversible blindness.
Insecurity remains a major obstacle to completing the elimination drive. The Chairman of the National Trachoma Task Force, Adamu Mohammed, said seven of the 11 remaining endemic LGAs are in Borno State, where security challenges have restricted access to affected communities.
Nigeria's progress has been driven by the implementation of WHO's SAFE strategy, supported by mass antibiotic distribution, eye surgeries, hygiene promotion and improved access to water and sanitation.
A study published in the International Health journal in January 2025 documented that Nigeria had distributed more than 34 million antibiotic treatments in 104 LGAs by 2021, while 102,527 people had received treatment for trachomatous trichiasis.
The study, titled Progress towards the elimination of trachoma in Nigeria, concluded that eliminating the disease by 2030 was feasible, provided funding support was sustained.
Trachoma is among the 21 diseases and disease groups covered by WHO's Neglected Tropical Diseases Roadmap 2021–2030, which seeks to accelerate prevention, control, elimination and eradication efforts, particularly among populations living in poverty and underserved communities.
Trachoma is caused by the bacterium Chlamydia trachomatis and spreads through contact with eye and nasal discharge from infected people. Repeated infections can cause scarring of the inner eyelid, forcing the eyelashes to turn inward and scratch the eyeball. Without treatment, the condition can cause irreversible blindness.
The disease disproportionately affects poor and underserved communities, particularly those with inadequate access to clean water, sanitation, hygiene facilities and essential healthcare. Despite significant global progress, the disease remains a public health challenge in parts of the world.
According to WHO, the global population requiring interventions against trachoma has fallen from an estimated 1.5 billion in 2002 to fewer than 100 million by November 2025, representing a reduction of about 94 per cent.
However, as of March 2026, approximately 92 million people still lived in trachoma-endemic areas and remained at risk of blindness. The disease continued to pose a public health problem in at least 29 countries. In 2025 alone, 98,829 people underwent surgery for advanced trachoma, while 47.4 million received antibiotics.
No comments:
Post a Comment